Home / Market News / $INDV

$INDV news and market catalysts

The 6 most recent market catalysts affecting $INDV, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

6 catalysts 4 high impact 3 bullish 1 bearish Pharmaceuticals
Oct 29, 2026 Corporate Catalyst Neutral Impact 95
Indivior Reports Q3 2026 Results and Confirms Imminent Merger with Supernus
Indivior's 8-K filing confirms the final stages of its merger with Supernus Pharmaceuticals, a major corporate event. This all-stock transaction will result in Indivior ceasing to …
Oct 29, 2026 Corporate Catalyst Bullish Impact 92
Indivior Reports Third Quarter 2026 Financial Results
Indivior Pharmaceuticals reported a strong third quarter for 2026, with total net revenue up 13% year-over-year and record net income and adjusted EBITDA. This positive financial p…
Sep 17, 2026 Corporate Catalyst Neutral Impact 95
Indivior Announces $8.13/Share Special Cash Dividend, Payable On Or About November 6 To Holders Of Record October 30, Contingent On Closing Of Supernus Merger
The announcement of an $8.13/share special cash dividend for Indivior is a major positive catalyst for its shareholders, representing a significant return of capital. However, this…
Aug 5, 2026 Market Technicals Bearish Impact 55
Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43
Barclays analyst Glen Santangelo maintained an 'Overweight' rating on Indivior Pharmaceuticals (INDV), signaling continued confidence in the company's fundamentals. However, the pr…
Aug 3, 2026 Corporate Catalyst Bullish Impact 75
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.215B-$1.285B to $1.295B-$1.365B vs $1.245B Est
Indivior Pharmaceuticals (INDV) has raised its FY2026 sales outlook from a previous range of $1.215 billion-$1.285 billion to a new range of $1.295 billion-$1.365 billion. This upw…
Aug 3, 2026 Corporate Catalyst Bullish Impact 85
Indivior Q2 Adj. EPS $1.15 Beats $0.87 Estimate, Sales $343.000M Beat $307.550M Estimate
This headline is a significant corporate catalyst for Indivior. The substantial beat on both adjusted EPS and sales estimates suggests stronger-than-anticipated product demand or b…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.